Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Total Revenue
1,313,646
1,116,854
889,895
751,040
Cost of Revenue
241,786
209,620
152,008
129,764
Gross Profit
1,071,860
907,234
737,887
621,276
Operating Expenses
Research Development
610,753
661,905
634,806
461,543
Selling General and Administrative
554,336
476,593
402,271
302,156
Non Recurring
--
--
--
--
Others
(78,529)
572,165
(188,488)
(49,532)
Total Operating Expenses
1,086,560
1,710,663
848,589
714,167
Operating Income or Loss
(14,700)
(803,429)
(110,702)
(92,891)
Income from Continuing Operations
Total Other Income/Expenses Net
6,679
4,391
(38,773)
(1,272)
Earnings Before Interest And Taxes
6,832
(791,551)
(144,974)
(88,226)
Interest Expense
42,707
39,499
9,750
36,642
Income Before Tax
(35,875)
(831,050)
(154,724)
(124,868)
Income Tax Expense
81,167
(200,840)
17,075
9,101
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(117,042)
(630,210)
(171,799)
(133,969)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(117,042)
(630,210)
(171,799)
(133,969)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(117,042)
(630,210)
(171,799)
(133,969)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: [email protected]

Global Medical Information

Contact Global Medical Information